title: [Effect of betamethasone in blood glucose levels in pregnant diabetic women at risk of preterm birth].
abstract: BACKGROUND
  The bethametasone (BTM) induced hyperglycemia is not adequately known and managed in diabetic pregnant women.
  
  
  OBJECTIVE
  To compare the betamethasone-induced hyperglycemia in pregnant women either healthy or with gestational or type 2 diabetes mellitus (diabetes mellitus).
  
  
  METHODS
  Forty volunteer pregnant women at risk of premature rupture of membranes who received betamethasone (12 mg i.m. every 24 hours, 2 doses) were divided in four groups (10 women each): G1, healthy; G2, Diet treated diabetes mellitus; G3, Diet plus insulin treated diabetes mellitus; G4, type 2 diabetes mellitus treated with diet (n=6) or diet and insulin (n=4). Pre (p) and 2h-postprandial (pp) capillary blood glucose was measured throughout the day during 5 days of hospitalization. Student't test for independent and dependent samples was used.
  
  
  RESULTS
  G1 had no significant changes in p or pp glucose. In G2 four women required de novo insulin administration while insulin dose was increased 39 to 112% and 26 to 64% in all women in G3 and G4, respectively to maintain p and pp glucose levels <95 mg/dL and < 120 mg/dL, respectively. The greatest changes occurred between days 2 to 4 after betamethasone.
  
  
  CONCLUSIONS
  Betamethasone-induced hyperglycemia was greater in insulin treated women with gestational or type 2 diabetes and should not be administrated on an out-patient basis.
authors.affiliation: Departamento de Endocrinologia, Instituto Nacional de Perinatología, Isidro Espinosa de los Reyes, México. maurorart@hotmail.com
authors.forename: María Aurora
authors.initials: MA
authors.lastname: Ramírez-Torres
authors.forename: Sandra Elia
authors.initials: SE
authors.lastname: Pérez-Monter
authors.forename: Salvador
authors.initials: S
authors.lastname: Espino y Sosa
authors.forename: Francisco
authors.initials: F
authors.lastname: Ibargüengoitia-Ochoa
mesh_terms: D000293:Adolescent; D000328:Adult; D001623:Betamethasone / Q000009:adverse effects* / Q000627:therapeutic use; D001724:Birth Weight; D001786:Blood Glucose / Q000032:analysis*; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D016640:Diabetes, Gestational / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000188:drug therapy / Q000517:prevention & control*; D010120:Oxytocics / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010120:Oxytocics; D001623:Betamethasone